AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00979992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00979992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT00619359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Aprepitant
Description: Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
Study NCT00619359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
Study NCT00619359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
Study NCT00619359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: single IV dose of 32 mg of ondansetron on Day 1.
Study NCT00619359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: single IV dose of 32 mg of ondansetron on Day 1.
Study NCT01780779 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment.
Study NCT02617524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valve Medical Dedicated Sheath version 00
Description: The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
Study NCT00725621 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
Study NCT02595008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS
Description: Active treatment
Study NCT01815112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
Study NCT02740595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one time exposure to e-cig with nicotine
Description: one time exposure to e-cig vapor with nicotine
Study NCT02740595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one time exposure to e-cig without nicotine
Description: one time exposure to e-cig without nicotine
Study NCT02740595 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: one time exposure to empty e-cig
Description: one time exposure to empty e-cig (sham control
Study NCT00507689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
Study NCT00507689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B Immunoglobulin (HBIg)
Description: HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
Study NCT02671344 — intervention group
Intervention type: OTHER
Intervention: Determination of gene profiles using arrays semen
Description: Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
Study NCT02100371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
Study NCT00495417 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE AD01
Description: s.c. injection
Study NCT01757405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIIa BI (rFVIIa BI)
Description: Administered approximately every 3 hours as an intravenous bolus injection on-demand
Study NCT00495417 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE AD01 adjuvanted
Description: s.c. injection
Study NCT01161563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin pamoate
Description: Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
Study NCT01161563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
Study NCT00660439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist.
Study NCT02957981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Counseling
Description: The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
Study NCT02957981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
Study NCT02863900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cohort of BC of each subtypes
Study NCT01807663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: healthy volonteers
Description: Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
Study NCT01807663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free breath monitoring
Description: Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
Study NCT03953222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable real-time feedback device
Description: The proposed wearable device can provide real-time feedback of primary gait and posture measures through auditory feedback. The feasibility of people with Parkinson's disease (PD) to utilize to feedback to modulate and improve their gait and posture will be investigated. Two types of feedback will be studied: (a) continuous feedback involving sonification of movements to facilitate learning proper movements (such as to take big steps, swing arms, rhythmic walking, maintain upright posture, etc.) and (b) on-demand feedback where the feedback is provided only if necessary to reduce overload of information and prevent developing dependency on the system.
Study NCT04412018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Description: Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
Study NCT03894891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a type of immunotherapy.
Study NCT03894891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a chemotherapy drug.
Study NCT03894891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is a chemotherapy drug.
Study NCT03894891 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: IMRT is definitive treatment for head and neck cancer.
Study NCT02750930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
Study NCT02750930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-injector
Description: The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
Study NCT01287494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
Study NCT00608062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHant - Ganirelix acetate
Description: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
Study NCT00608062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GnRHant - Ganirelix acetate
Description: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
Study NCT00608062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patch
Description: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
Study NCT00608062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal placebo patch
Description: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
Study NCT04349683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jinshuibao
Description: 6 capsules at a time, 3 times a day (tid).
Study NCT04349683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules at a time, 3 times a day (tid).
Study NCT01757405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIIa BI (rFVIIa BI)
Description: Administered as a single intravenous bolus injection on-demand
Study NCT04343313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Half Moon TMVr System
Description: The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
Study NCT00343291 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Administered intravenously
Study NCT00343291 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered intravenously
Study NCT00343291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously
Study NCT00343291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously
Study NCT01956240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching-Asymptomatic subjects
Description: The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
Study NCT01956240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching-Subjects with shoulder pain
Description: The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
Study NCT02517593 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Polygenic Risk Score
Description: A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (>40%).
Study NCT01504386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
Study NCT01504386 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TAP block
Description: Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
Study NCT03034759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individualized insulin sensitivity index (ISind)
Description: The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads.
Study NCT04793854 — intervention group
Intervention type: OTHER
Intervention: Measure of the Life habits (MHAVIE)
Description: Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).~Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,...).
Study NCT00218426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone implant
Description: naltrexone implant is 1000 mg naltrexone
Study NCT00218426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naltrexone
Description: oral naltrexone 50 mg/day
Study NCT00218426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral placebo naltrexone
Description: oral placebo naltrexone resembles active medication
Study NCT00218426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo naltrexone
Description: oral placebo naltrexone resembles active medication
Study NCT00218426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo implant
Description: placebo implant resembles active medication
Study NCT00218426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo implant
Description: placebo implant resembles active medication
Study NCT05254613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).
Study NCT05254613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).
Study NCT02338492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic Bone Stabilization System
Description: Treatment of impending and actual pathological fractures of the humerus
Study NCT03677895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
Study NCT00582062 — intervention group
Intervention type: OTHER
Intervention: washings for experimental marker testing
Description: During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
Study NCT02049801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK inhibitor MEK162
Description: Given PO
Study NCT02049801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT02049801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT02049801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02049801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01993862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Same Day Discharge
Description: Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
Study NCT02470052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OL-BF-001
Description: Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
Study NCT00155454 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intravitreal long acting gas (10% C3F8)
Description: At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
Study NCT00155454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal long acting gas (10% C3F8)
Description: At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
Study NCT03279302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Description: Solution for injection
Study NCT03329651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Description: Daily treatment with metformin tablets for 24 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2
Study NCT03329651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2
Study NCT01035242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: association splitting
Description: Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened.
Study NCT01035242 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive remediation
Description: Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
Study NCT04316663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-Being Intervention
Description: The main aim of the well-being intervention is to reduce levels of distress through the promotion of psychological well-being. Key components of the intervention are self-monitoring of instances of well-being and what leads to their interruption (i.e., thoughts and behaviors), cognitive restructuring of interfering thoughts, and homework assignments to address dysfunctional behaviors and increase exposure to optimal experiences. Participants will become aware of their functioning based on six different dimensions of psychological well-being (i.e., self-acceptance, positive relations with others, autonomy, environmental mastery, purpose in life, and personal growth), and will be guided in finding a balance within each dimension.
Study NCT04316663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.
Study NCT04316663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene
Description: The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.
Study NCT01815112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
Study NCT04328519 — intervention group
Intervention type: OTHER
Intervention: observation
Description: observation